Enliven Therapeutics has raced ahead with a 220.6% year to date return, yet the broader valuation checks and market multiples now lean toward the stock looking expensive rather than like an obvious bargain. The year to date gain of 220.6% suggests expectations around Enliven Therapeutics have reset significantly higher and leaves less room for disappointment. Upcoming work on the ENABLE-2 Phase 3 trial for ELVN-001 can support long term value if progress continues as planned, while recent...